Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2013) David Moher   ANNALS OF INTERNAL MEDICINE

Incretin-based therapies and cardiovascular risk

(2012) Edoardo Mannucci et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease

(2012) J. Hong et al.   DIABETES CARE

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

(2012) M. Monami et al.   DIABETES OBESITY & METABOLISM

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

(2012) Baptist Gallwitz et al.   LANCET

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

(2012) Baptist Gallwitz et al.   LANCET

Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: Impact on cardiovascular events. A randomized controlled trial

(2012) O. Vaccaro et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

(2011) Matteo Monami et al.   CURRENT MEDICAL RESEARCH AND OPINION

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial

(2011) M. A. Nauck et al.   DIABETES CARE

Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus

(2011) Ligia Petrica et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients

(2011) Giuseppe Derosa et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Pioglitazone Compared to Glibenclamide on Lipid Profile and Inflammation Markers in Type 2 Diabetic Patients During an Oral Fat Load

(2011) G. Derosa et al.   HORMONE AND METABOLIC RESEARCH

Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

(2010) Hertzel C. Gerstein et al.   CIRCULATION

Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus

(2010) Thomas Forst et al.   CLINICAL SCIENCE

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes

(2010) Y. Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial

(2010) R. Arechavaleta et al.   DIABETES OBESITY & METABOLISM

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials

(2010) C. Lamanna et al.   DIABETES OBESITY & METABOLISM

Exenatide Versus Glibenclamide in Patients with Diabetes

(2010) G. Derosa et al.   Diabetes Technology & Therapeutics

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

(2010) C. Filozof et al.   DIABETIC MEDICINE

Effects of One Year Treatment of Vildagliptin Added to Pioglitazone or Glimepiride in Poorly Controlled Type 2 Diabetic Patients

(2010) G. Derosa et al.   HORMONE AND METABOLIC RESEARCH

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

(2010) T. Seck et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

(2010) B. Göke et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial

(2010) Ligia Petrica et al.   WIENER KLINISCHE WOCHENSCHRIFT

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

(2009) E. Ferrannini et al.   DIABETES OBESITY & METABOLISM

Liver Safety in Patients with Type 2 Diabetes Treated with Pioglitazone

(2009) Keith G. Tolman et al.   DRUG SAFETY

Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naïve Patients with Type 2 Diabetes

(2009) J. E. Foley et al.   HORMONE AND METABOLIC RESEARCH

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

(2009) Philip D Home et al.   LANCET

Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus

(2009) Rodica Pop-Busui et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study

(2009) Giuseppe Derosa et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Prevention of cardiovascular disease through glycemic control in type 2 diabetes: A meta-analysis of randomized clinical trials

(2009) E. Mannucci et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes

(2008) Katerina Papathanassiou et al.   ATHEROSCLEROSIS

Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride

(2008) Cindy J Rubin et al.   Diabetes & Vascular Disease Research

Rosiglitazone-Associated Fractures in Type 2 Diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT)

(2008) S. E. Kahn et al.   DIABETES CARE

Comparison of Gliclazide with Insulin as Initial Treatment Modality in Newly Diagnosed Type 2 Diabetes

(2008) Satish T. Chandra et al.   Diabetes Technology & Therapeutics

Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes

(2008) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pioglitazone and Heart Failure: Results From a Controlled Study in Patients With Type 2 Diabetes Mellitus and Systolic Dysfunction

(2008) Thomas D. Giles et al.   JOURNAL OF CARDIAC FAILURE

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET

Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus—An effect probably mediated by direct platelet PPARγ activation

(2007) M.P. Khanolkar et al.   ATHEROSCLEROSIS

Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes

(2007) H. S. Chou et al.   DIABETES OBESITY & METABOLISM